Business Wire (Wed, 4:01PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,295 people get BIIB articles and Market Currents by email alert.
Get email alerts on BIIB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Tue, 4:30AM)
-
-
-
Business Wire (May 13, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (Apr 25, 2013)
-
-
-
-
-
-
Tecfidera Raises The Bar For Biogen IdecBrian L. Wilson • Mon, Apr 1 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biogen: A 'Decimated' Pipeline?Derek Lowe • Tue, Jan 17, 2012 -
Biogen Idec: Q3 Clues To ValueWilliam Meyers • Thu, Nov 3, 2011
-
Biogen Idec: Fairly Priced With A Healthy Balance SheetRon Sommer • Mon, Sep 12, 2011
-
Biogen Idec's CEO Hosts 2012 Analyst Day (Transcript)Tue, Jun 12, 2012 • 1 Comment
-
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012
-
Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Biogen Idec Inc. - Special CallWed, Oct 26, 2011
-
Biogen Idec's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 26, 2011
-
Biogen Idec's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 21, 2011
-
Biogen Idec CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Biogen Idec Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Biogen Idec, Inc. Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Biogen Idec, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 9, 2010 • 1 Comment
-
Biogen Idec Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Biogen Idec Inc., Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
Business Wire (Wed, 4:01PM)
-
Business Wire (Tue, 4:30AM)
-
at CNBC.com (May 14, 2013)
-
Business Wire (May 13, 2013)
-
at CNBC.com (May 9, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at MarketWatch.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 18, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 12, 2013)
BIIB vs. ETF Alternatives
Company Description
Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, April 12, 10:59 AM Elan's (ELN -1.3%) shareholders have overwhelmingly approved a plan to buy back $1B in stock following the sale of Tsabri to Biogen Idec (BIIB +2.4%), as speculation mounts that an earlier takeover indication by Royalty Pharma might be sweetened. Royalty approached ELN in February with an $11 per share potential offer, valuing the company at $6.55B, which was rejected by ELN. Last week, Ireland's Takeover Panel told the pharmaceutical investor to either step up and announce an official takeover offer for the company by May 10, or walk away. Comment! [Healthcare, Global & FX, M&A]
- Tuesday, April 2, 6:08 PM Biogen Idec (BIIB) completes its purchase of Elan's (ELN) interest in Tysabri, gaining full strategic, commercial and decision-making rights to the relapsing MS drug treatment. [BIIB plans to give further details and updated financial guidance during it's upcoming Q1 earnings announcement. Shares +0.3% AH. Comment! [Healthcare, M&A]
- Wednesday, February 6, 4:08 PM Deutsche Bank cuts Elan (ELN -9.9%) to Hold on the back of its sale of Tysabri to Biogen (BIIB +2.1%). Deutsche says the decision looks attractive because ELN "swapped hope for certainty." However, uncertainty over the use of the proceeds forces it to move to the sidelines. Comment! [Healthcare, M&A, On the Move]
- Wednesday, February 6, 3:16 AM Biogen Idec (BIIB) has agreed to acquire full ownership of multiple-sclerosis drug Tysabri from Elan (ELN) for $3.25B plus future royalty payments. Biogen has co-marketed the injectable treatment, which generated revenue of $1.6B last year, with Elan for twelve years, with both firms splitting the profit until now. The deal comes as Biogen awaits approval for its BG-12 pill to treat MS. (PR) 1 Comment [Healthcare, Top Stories, M&A]
- Tuesday, February 14, 2012, 9:08 AM Biogen (BIIB) agrees to acquire Stromedix, a privately-held developer of treatments for fibrosis and organ failure, for $75M in cash and potential additional payments of up to $487.5M. Stromedix's most advanced candidate, STX-100, is a monoclonal antibody that has shown promise in early stage trials to treat fibrosis. BIIB -0.5% premarket. Comment! [Healthcare, M&A]
- Monday, October 17, 2011, 6:13 PM GlaxoSmithKline (GSK) may bid $25/share for Human Genome Sciences (HGSI), the Daily Mail speculates, citing their partnership in developing the FDA-approved lupus drug Benlysta. With Merck (MRK) and Biogen (BIIB) also sniffing around the company, GSK "could decide now would be an opportune time to make a move on HGS." HGSI +4.9% AH. 2 Comments [Healthcare, M&A]
-
Kenneth Hackel
Last week CT Capital sold $BIIB after tripling and bought #QCOR at $30.96, up 30% in a week. - View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 25 2013 | $AKAM $ALNX $BIIB $CROX $INFN $LSI $PERI $YNDX | SharePlanner http://bit.ly/12Kc6ip - View all 0 replies
-
- View all 1 replies
-
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signals - 11 new highs and up 15.13% in the last month - Relative Strength Index 78.77% - View all 0 replies
-
Michael Bryant
Biogen Idec ($BIIB) is surging higher. Still more bight days ahead for the biotech giant. http://yhoo.it/XWT1oi;c= - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signal - 11 new highs and up 8.90% in the last month - Relative Strength Index 70.31% - View all 0 replies
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
-
- View all 3 replies
-
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list. -
-
- View all 3 replies
-
-
-
- View all 5 replies
-
-
-
- View all 4 replies
-
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day. -
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 1 replies
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.